Genetics of psychosis in Alzheimer's disease: a review.
In and of itself, late-onset Alzheimer's disease (AD) can be a devastating illness. However, a sub-group of AD patients develop psychosis as the disease progresses. These patients have an added burden of greater cognitive impairment, higher rates of institutionalization, and higher mortality than AD patients without psychosis. While the etiopathogenesis such as psychosis in AD (AD+P) is not known, mounting evidence accrued over the past ten years indicates that AD+P represents a distinct phenotype with a genetic basis. Elucidating the genetic mechanism of AD+P is crucial if better pharmaceutical treatments are to be developed for these patients. The goal of this review is to summarize what is currently known regarding the genetic basis of psychosis in AD. Specific attention is given to familial aggregation and heritability, linkage to chromosomal loci, and associations of candidate genes of APOE and the monoamine neurotransmitter system.
DeMichele-Sweet
Mary Ann
MA
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Sweet
Robert A
RA
D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology*; D001057:Apolipoproteins E / Q000235:genetics*; D015897:Comorbidity; D056726:Genetic Association Studies; D008040:Genetic Linkage; D006801:Humans; D008995:Monoamine Oxidase / Q000235:genetics; D020890:Neuregulin-1 / Q000235:genetics*; D011618:Psychotic Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics*; D012701:Serotonin / Q000235:genetics
D001057:Apolipoproteins E; C094131:NRG1 protein, human; D020890:Neuregulin-1; D012701:Serotonin; D008995:Monoamine Oxidase